Unipharma Co (ROCO:6621) Total Receivables: NT$14.97 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6621 Unipharma Co Ltd ROCO:6621
71 GF Score
Price NT$11.55
GF Value NT$11.54
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Unipharma Co Total Receivables?

Unipharma Co ROCO:6621 +4.52% 71 Total Receivables is NT$14.97 Mil as of Dec. 2025. GuruFocus rates ROCO:6621 with a GF Score™ of 71/100 and a GF Value™ of NT$11.54 (Fairly Valued). The stock has 2 warning signs investors should review.

Unipharma Co's Total Receivables for the quarter that ended in Dec. 2025 was NT$14.97 Mil.

Unipharma Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Unipharma Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unipharma Co Total Receivables Chart

Unipharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.98 34.10 21.25 16.86 14.97

Unipharma Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.25 19.70 16.86 16.04 14.97
ROCO:6621
71GF Score
Unipharma Co Ltd ROCO:6621
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unipharma Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of NT$14.97 Mil mean?
Unipharma Co (ROCO:6621) has a Total Receivables of NT$14.97 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Unipharma Co and its competitors.
Is Unipharma Co's Total Receivables too high?
Unipharma Co's current Total Receivables is NT$14.97 Mil. Overall, Unipharma Co has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's Total Receivables compare to ZTS?
Unipharma Co's Total Receivables of NT$14.97 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Unipharma Co and its competitors. Unipharma Co's current Total Receivables is NT$14.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.54, compared to a current price of NT$11.55 — trading 0.1% above its estimated fair value. The current Total Receivables is NT$14.97 Mil. Unipharma Co's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current Total Receivables is NT$14.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Unipharma Co (ROCO:6621) Overvalued in 2026?

Based on GuruFocus' analysis, Unipharma Co stock appears to be overvalued. The current stock price of NT$11.55 is trading 0.1% above its estimated GF Value™ of NT$11.54. GuruFocus considers Unipharma Co to be Fairly Valued.

Key valuation signals for ROCO:6621:

  • Total Receivables: NT$14.97 Mil
  • GF Value™: NT$11.54 vs. price of NT$11.55 (0.1% above fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Unipharma Co Business Description

Address Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
71GF Score

Get the complete analysis for ROCO:6621

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$11.55
Price
NT$11.54
GF Value